CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.
The combination of nivolumab (Opdivo, Bristol Myers Squibb) and ipilimumab (Yervoy, Bristol Myers Squibb) reduced risk for progression or death by 79% compared with chemotherapy, findings presented at ASCO Annual Meeting showed.
An analysis of outcomes after subsequent therapy also strongly favored the combination.
“These are practice-changing data,”